Annals of Internal Medicine, tip sheet, June 6, 2000

June 05, 2000

Hangovers have psychological, physical and job-related consequences

The alcohol hangover places stress on the heart, impairs learning and visual-spatial acuity, which can limit job performance and driving ability, and costs billions of dollars each year from employee absences and decreased productivity (Review, p. 897). Because of this, the authors say, screening for hangovers is reasonable and may be one of the best ways to find patients' problems with alcohol. Of treatments surveyed, only drinking fluids and taking vitamin B6 tablets seemed to reduce hangover symptoms.
* * *

Long-term anticoagulant probably not needed after knee or hip surgery

Although the anticoagulant low-molecular-weight heparin is often used after knee and hip replacement surgery to prevent development of leg blood clots, a new study found that extended out-of-hospital use does not significantly reduce venous thromboembolism or death (Article, p. 853). An editorial says that the most promising approaches to prevent leg blood clots after knee and hip replacement surgery are to minimize clot formation while patients are in the hospital and lower the cost of the drug (Editorial, p. 914).
* * *

Recombinant hormone may help scleroderma

In an early drug trial, recombinant human relaxin significantly reduced skin thickening and improved mobility in patients with moderate to severe diffuse scleroderma (Article, p. 871). Scleroderma is a progressive, disabling disease in which the skin and some internal organs harden. It is difficult to treat, and no therapies to date prevent or reverse the hardening. In the phase-two trial involving 68 patients, recombinant human relaxin showed promise at a dose of 25 micrograms of body weight per day for 24 weeks but had no effect at 100 micrograms.
Annals of Internal Medicine is published by the American College of Physicians-American Society of Internal Medicine (ACP-ASIM), an organization of more than 115,000 physicians trained in internal medicine. The following highlights are not intended to substitute for articles as sources of information. For an embargoed fax of an article, call 800-523-1546, ext. 2656 or 215-351-2656. Full content of the issue will be available on the Internet at on June 6, 2000.

American College of Physicians

Related Scleroderma Articles from Brightsurf:

Novel educational program puts a human face on biomedical research
The goal of translational research is to speed research breakthroughs into clinical practice.

Higher estrogen levels linked to more severe disease in scleroderma
Scleroderma is a connective tissue disease that hardens the skin and scars the organs.

New regulator of immune responses discovered
Scientists have identified a new internal regulator which helps control the body's response to fight infection.

Inhibiting cancer-causing protein could prevent scleroderma fibrosis
Examining the autoimmune disease at the molecular level led researchers to a specific molecule that could be contributing to the disease progression in patients.

Potential therapeutic target for lung fibrosis identified
No current treatments reverse or stop lung fibrosis -- scarring of the lung that makes it difficult to breathe.

Regulatory and effector B cells control scleroderma
A Japan-based research team led by Kanazawa University have found reciprocal regulation of B cells on bleomycin-induced scleroderma model.

Why internal scars won't stop growing
A study has newly identified an immune trigger of some fibrotic diseases and an experimental compound to treat it.

New treatment lenebasum shows promise for diffuse cutaneous systemic sclerosis (dcSSc)
The results of an open label extension of a phase II study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that lenabasum continues to have acceptable safety and tolerability in diffuse cutaneous systemic sclerosis (dcSSc) with no severe or serious adverse events (AE).

Uncovering a mechanism causing chronic graft-vs-host disease after bone marrow transplant
MicroRNA-17-92 is required for the T-cell and B-cell pathogenicity that drives chronic graft-versus-host disease (cGVHD) after allogeneic bone marrow transplant (BMT), report investigators at The Medical University of South Carolina in an article prepublished online March 12, 2018 by Blood.

LJI researchers discover key driver of atopic dermatitis
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction.

Read More: Scleroderma News and Scleroderma Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to